Generation Bio Co. (GBIO)

Market Cap	79.48M
Revenue (ttm)	18.58M
Net Income (ttm)	-145.47M
Shares Out	66.79M
EPS (ttm)	-2.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	697,776
Open	1.060
Previous Close	1.080
Day's Range	1.060 - 1.210
52-Week Range	0.750 - 4.650
Beta	2.66
Analysts	Strong Buy
Price Target	7.50 (+530.25%)
Earnings Date	Nov 6, 2024

About GBIO

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating epi...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 12, 2020
• Employees: 174
• Stock Exchange: NASDAQ
• Ticker Symbol: GBIO
• Website: https://generationbio.com

Analyst Forecast

According to 2 analysts, the average rating for GBIO stock is "Strong Buy." The 12-month stock price forecast is $7.5, which is an increase of 530.25% from the latest price.

Price Target

$7.5

(530.25% upside)

Analyst Consensus: Strong Buy